Based on their direct role in tumor cell cytolysis, adoptive T cell therapy using tumor-specific T cells has long focused on cytotoxic CD8+ T cells, however, the transferred tumor-specific CD8+ T cells mostly differentiate into CD39+CD69+ exhausted cells, which are poorly maintained as tumor progresses (5), leading to limited success in tumor repression. This evidence concerns the gene CD69 and neoplasm.